Comment | Published:

Why patients receive treatments that are minimally effective?

Nature Reviews Clinical Oncologyvolume 16pages34 (2019) | Download Citation

The value of medical treatments is an issue that has been actively debated in recent years and is not unique to oncology. In this Comment, we discuss why we pursue treatments which might have limited benefit from the point of view of three parties: the patient, the physician, and the pharmaceutical industry.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Davis, C. et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 359, j4530 (2017).

  2. 2.

    Weeks, J. C. et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N. Engl. J. Med. 367, 1616–1625 (2012).

  3. 3.

    Duric, V. M. et al. Patients’ preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann. Oncol. 16, 1786–1794 (2005).

  4. 4.

    Verma, A. A., Razak, F. & Detsky, A. S. Understanding choice: why physicians should learn prospect theory. JAMA 311, 571–572 (2014).

  5. 5.

    Duggan, K. T. et al. Use of word “unprecedented” in the media coverage of cancer drugs: do “unprecedented” drugs live up to the hype? J. Cancer Policy 14, 16–20 (2017).

  6. 6.

    Booth, C. M. & Eisenhauer, E. A. Progression-free survival: meaningful or simply measurable? J. Clin. Oncol. 30, 1030–1033 (2012).

  7. 7.

    Boutron, I. et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303, 2058–2064 (2010).

  8. 8.

    Del Paggio, J. C. et al. Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit? Ann. Oncol. 28, 157–162 (2016).

  9. 9.

    Tibau, A. et al. Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration. J. Natl Cancer Inst. 110, 486–492 (2018).

  10. 10.

    Del Paggio, J. C. et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 18, 887–894 (2017).

Download references

Acknowledgements

The authors gratefully acknowledge V. Chopra and I. Tannock for their helpful comments on an earlier draft of this manuscript.

Author information

Affiliations

  1. Department of Oncology, Queen’s University, Kingston, Ontario, Canada

    • Christopher M. Booth
  2. Division of Cancer Care and Epidemiology, Queen’s Cancer Research Institute, Kingston, Ontario, Canada

    • Christopher M. Booth
  3. Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

    • Allan S. Detsky
  4. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

    • Allan S. Detsky
  5. Department of Medicine, Mount Sinai Hospital and University Health Network, Toronto, Ontario, Canada

    • Allan S. Detsky

Authors

  1. Search for Christopher M. Booth in:

  2. Search for Allan S. Detsky in:

Competing interests

The authors have no competing interests.

Corresponding author

Correspondence to Christopher M. Booth.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41571-018-0101-4

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing